Psychotropic medication use in children with autism in the Kentucky Medicaid population

Clinical Pediatrics

Volumn 51, Issue 10, 2012, Pages 923-927

  Williams, P Gail ^a   Woods, Charles ^a   Stevenson, Michelle ^a   Davis, Deborah Winders ^a   Radmacher, Paula ^a   Smith, Michael ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

autism; Kentucky Medicaid population; psychotropic drug

Indexed keywords

ATENOLOL; ATOMOXETINE; CARBAMAZEPINE; CHLORAL HYDRATE; CITALOPRAM; CLONAZEPAM; DEXAMPHETAMINE; ETIRACETAM; FLUOXETINE; FLURAZEPAM; GABAPENTIN; LAMOTRIGINE; LISDEXAMFETAMINE; LORAZEPAM; METHYLPHENIDATE; METOPROLOL; OXCARBAZEPINE; PHENOBARBITAL; PROPRANOLOL; PSYCHOTROPIC AGENT; QUETIAPINE; RAMELTEON; RISPERIDONE; SERTRALINE; TEMAZEPAM; TOPIRAMATE; TRAZODONE; UNINDEXED DRUG; VALPROIC ACID; ZOLPIDEM;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; AUTISM; BEHAVIORAL MEDICINE; CHILD; CHILD HEALTH CARE; DRUG USE; EDUCATION; FEMALE; HEALTH SERVICE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAID; PRESCHOOL CHILD; PRESCRIPTION; SCHOOL CHILD; UNITED STATES;

ADOLESCENT; AGE DISTRIBUTION; AUTONOMIC AGENTS; CENTRAL NERVOUS SYSTEM AGENTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; DRUG UTILIZATION; HUMANS; INFANT; KENTUCKY; MEDICAID; PSYCHOTROPIC DRUGS; UNITED STATES;

EID: 84873694760     PISSN: 00099228     EISSN: 19382707     Source Type: Journal    
DOI: 10.1177/0009922812440837     Document Type: Article

References (22)

1. Prevalence of autism spectrum disorders - Autism Developmental Disabilities Monitoring Network, United States, 2006. MMWR Surveill Summ. 2009 ; 58 (10). 1-20
2. Kogan MD, Blumberg SJ, Schieve LA, et al. Prevalence of parent-reported diagnosis of autism spectrum disorders among children in the US, 2007. Pediatrics. 2007 ; 124: 1395-1403
3. Myers S, Johnson C. Management of children with autism spectrum disorders. Pediatrics. 2007 ; 120: 1162-1182 (Pubitemid 350085560)
4. Simonoff E, Pickles A, Charman R, Chandler S, Loucas T, Baird G. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry. 2008 ; 47: 921-929
5. Broadstock M, Doughty C, Eggleston M. Systematic review of the effectiveness of pharmacologic treatment for adolescents and adults with autism spectrum disorders. Autism. 2007 ; 11: 335-348 (Pubitemid 47244226)
6. United States Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health, Mental Health Medications, NIH Publication 08-3929, 2008. http://www.nimh.nih.gov/health/ publications/mental-health-medications/complete-index.shtml.Accessed July 29, 2011.
7. Owen R, Sikich L, Marcus R, et al. Aripirazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009 ; 124: 1533-1540
8. Collins FL Pediatric Focused Safety Review: Aripiprazole. Silver Spring, MD: US Food and Drug Administration ; 1-24.
9. Jesner OS, Aref-Adub M, Coren E. Risperidone use in autism. Cochran Database Syst Rev. 2007 ; ( 1 ):
10. Estes A. Psychotropic medications in autism. Paper presented at: 8th Annual International Meeting for Autism Research ; Chicago, IL ;..
11. Mandell D, Nirakes K, Marcus S, Stahmer A, Doshi J, Polsky D. Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics. 2008 ; 121: e441 - e3448
12. Aman MG, Bourgondien ME, Wolford PL, Sarphare G. Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use. J Am Acad Child Adolesc Psychiatry. 1995 ; 34: 1672-1681
13. Aman MG, Lam KS, Bourgondien ME. Medication patterns in patients with autism: temporal, regional and demographic influences. J Am Acad Child Adolesc Psychiatry. 2005 ; 15: 116-126 (Pubitemid 40365921)
14. Martin A, Scahill L, Klin A, Volkmar F. Higher-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use. J Am Acad Child Adolesc Psychiatry. 1999 ; 38: 923-931 (Pubitemid 29309854)
15. Witwer A, Lecavalier L. Treatment incidence and patterns in children and adolescents with autism spectrum disorders. J Child Adolesc Psychopharmacol. 2005 ; 15: 671-681 (Pubitemid 41434371)
16. Oswald DP, Sonenklar NA. Medication use among children with autism spectrum disorders. J Child Adolesc Psychiatry. 2007 ; 17: 348-355 (Pubitemid 47067958)
17. Langworthy-Lam K, Aman MA, Bourgondient ME. Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. J Child Adolesc Psychopharmacol. 2002 ; 12: 311-321 (Pubitemid 36169283)
18. Wigal T, Greenhill L, Chuang S. Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry. 2006 ; 45: 1294-1303 (Pubitemid 44665446)
19. Ucok A, Gaebel W. Side effects of atypical antipsychotics: a brief overview. World Psychiatry. 2008 ; 7: 58-62 (Pubitemid 351338194)
20. McIntyre R, Jerrell J. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Arch Pediatr Adolesc Med. 2007 ; 162: 929-935
21. Arnold LE, Vitiello B, McDougle CJ, et al. Patient-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry. 2003 ; 42: 1443-1450 (Pubitemid 39585974)
22. McDougle CJ, Scahill L, McCracken JT, et al. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network: background and rationale for an initial controlled study of risperidone. Child Adolesc Psychiatr Clin N Am. 2000 ; 9: 201-224 (Pubitemid 30261725)